Leukemia Market

Global Leukemia Market Size, Trends & Analysis - Forecasts to 2026 By Type (Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Acute Lymphocytic Leukemia, Acute Myeloid Leukemia), By Treatment Type (Chemotherapy, Targeted Drugs & Immunotherapy), By Molecule Type (Biologics, Small Molecules), By Mode of Administration (Oral Mode, Injectable Mode), By Region (North America, Europe, Asia Pacific, MEA, and CSA); End-User Landscape, Vendor Landscape, and Company Market Share Analysis and Competitor Analysis

Category Healthcare

Format

This report was recently updated on November 17 2024 with the latest and most recent market numbers

Leukemia Market Insights

The global leukemia market will grow from USD 13.21 billion in 2021 to reach USD 19.52 billion in 2026, with a CAGR of 6.52% from 2021 to 2026. Leukemia is a rapidly spreading blood cancer that occurs in the bone marrow and progresses to uncontrolled blood cell development. Leukemia is emerging as a life-threatening cancer disease across the globe. The leukemia therapeutics market includes a variety of therapies recommended by doctors for the treatment of leukemia. The factors supporting the leukemia market growth are the rising incidence of acute & chronic myeloid leukemia, rising research and developmental activities to launch non-invasive and advanced therapeutics for cancer treatment, increasing government expenditure on healthcare infrastructure and growing government initiatives for cancer awareness.

Cancer of white blood cells is also known as leukemia. White blood cells protect the body from a wide range of infections. Leukemia impacts red blood cells and platelets and can be acute or chronic. Fever, enlarged liver, weight loss, night sweats, frequent infections, and swollen lymph nodes are all common symptoms of leukemia. The rising geriatric patient population is also another major factor affecting the leukemia market size positively. As per a WHO report, leukemia is the most common blood cancer found in men, accounting for more than 60% percent of men and 40% percent of women worldwide.

The surge in cases of leukemia has fueled the expansion of the leukemia market, increasing innovation in drug discovery, the introduction of novel therapies, and promising pipeline drugs. Furthermore, the presence of various treatment options and a family history of leukemia are seen to be strong indicators of demand for innovative medications. Ongoing research in the field of molecular diagnosis is projected to lead to the availability of effective leukemia treatments, which will propel market expansion.

Hence, the leukemia market size will be growing rapidly owing to factors such as the increasing number of cancer cases, an increasing geriatric patient pool especially in developing regions, and increasing investment in the healthcare verticals. Moreover, patient awareness of the newest technological developments in therapies, as well as benefits such as safety, tolerability, and efficacy, are projected to drive leukemia cancer market growth.

global leukemia market

Leukemia Market: By Type

The leukemia market categorized its type segment into chronic myeloid leukemia, chronic lymphocytic leukemia, acute lymphocytic leukemia, and acute myeloid leukemia. The chronic myeloid leukemia segment is analyzed to be the fastest-growing segment in the market during the forecast period. It is due to the rising funds for research and the development of novel therapies supported by the government. Moreover, with high medication treatment rates, and rapid absorption of second-generation tyrosine kinase inhibitors, the chronic myeloid leukemia segment is dominant in the leukemia market.

Leukemia Market: By Treatment

Chemotherapy, and targeted drugs & immunotherapy, are the major segments of the leukemia treatment market. The targeted drugs segment will be the largest shareholder of the market owing to factors such as the increasing demand for targeted drugs. As compared to chemotherapy, targeted medications are the most extensively utilized as they have fewer side effects and a greater efficacy and success rate.

The chemotherapy segment will be the fastest-growing segment with the highest CAGR value from 2021 to 2026 due to rising cases of leukemia. As per the American Cancer Society, there were approximately 22,840 deaths from leukemia in the United States in 2019, resulting in the overall leukemia market growth.

Leukemia Market: By Mode of Administration

Oral and injectable are the two different modes of administration of the leukemia treatment market. The oral mode segment will be the largest shareholder of the market during the forecast period owing to the rising growth in biologics. Drugs administered orally have lesser complications are one of the leading factors of the market.

asia pacific leukemia market

Leukemia Market: By Region

As per the geographical analysis, the leukemia market can be classified into North America (the United States, Canada, and Mexico), Asia Pacific (India, China, Japan, Malaysia, Singapore, and the Rest of Asia Pacific), Europe (Germany, United Kingdom, Italy, France, Spain, Netherlands, and Rest of Europe), Middle East & Africa (Saudi Arabia, United Arab Emirates, and Rest of the Middle East & Africa) and Central & South America (Brazil, Argentina, and Rest of Central and South America). North America (the United States, Canada, and Mexico) will have a dominant share in the market during the forecast period. The high share of this region is mainly due to the presence of key players in the US market, increasing expenses in the healthcare sector, increasing investments in cell-based R&D activities, and increasing adoption of personalized medicine and rapidly rising prevalence of blood cancer in the US. Moreover, the growing government frameworks along with the rising healthcare infrastructure are some of the factors increasing the leukemia market in US over the forecast period.

However, on the contrary, the Asia Pacific region will grow with the highest CAGR rate in the market. Rising investments in research & innovation activities, growing disposable income, and increasing awareness of leukemia will impact the leukemia cancer market trends positively. Furthermore, the growing medical tourism industry in countries such as India, and China will help the APAC region grow the fastest from 2021 to 2026.

Leukemia Market Share and Competitor Analysis

F. Hoffmann-La Roche AG, Bristol-Myers Squibb Company, AbbVie, Inc., Sanofi, Amgen, Gilead Sciences, Celgene Corporation, Pfizer, Inc., Novartis AG, and Takeda Pharmaceutical Company Limited, among others are some of the key players in the Leukemia market.

Please note: This is not an exhaustive list of companies profiled in the report.

In January 2019, Amgen announced that it bagged the European Commission (EC) approval for BLINCYTO monotherapy. This helped the company expand its product portfolio and enhance its presence in the global leukemia market.

Chapter 1 Methodology

1.1 Market Scope & Definitions

1.2 Estimates & Forecast Calculation

1.3 Historical Data Overview and Validation

1.4 Data Sources

1.4.1 Secondary

1.4.2 Primary

Chapter 2 Report Outlook

2.1 Global Leukemia Industry Overview, 2020-2026

2.1.1 Industry Overview

2.1.2 Molecule Type Overview

2.1.3 Treatment Type Overview

2.1.4 Mode of Administration Overview

2.1.5 Type Overview

2.1.6 Regional Overview

Chapter 3 Leukemia Market Trends

3.1 Market Segmentation

3.2 Industry Background, 2020-2026

3.3 Market Key Trends

3.3.1 Positive Trends

3.3.1.1 Increasing incidence of leukemia

3.3.1.2 Rising demand for personalized medicines

3.3.2 Industry Challenges

3.3.2.1 High cost of leukemia therapies

3.4 Prospective Growth Scenario

3.4.1 Molecule Type Growth Scenario

3.4.2 Type Growth Scenario

3.4.3 Mode of Administration Growth Scenario

3.4.4 Treatment Type Growth Scenario

3.5 COVID-19 Influence over Industry Growth

3.6 Porter’s Analysis

3.7 PESTEL Analysis

3.8 Value Chain & Supply Chain Analysis

3.9 Regulatory Framework

3.9.1 North America

3.9.2 Europe

3.9.3 APAC

3.9.4 LATAM

3.9.5 MEA

3.10 Technology Overview

3.11 Market Share Analysis, 2020

3.11.1 Company Positioning Overview, 2020

Chapter 4 Leukemia Market, By Molecule Type

4.1 Molecule Type Outlook

4.2 Biologics

4.2.1 Market Size, By Region, 2020-2026 (USD Billion)

4.3 Small Molecules

4.3.1 Market Size, By Region, 2020-2026 (USD Billion)

Chapter 5 Leukemia Market, By Treatment Type

5.1 Treatment Type Outlook

5.2 Chemotherapy

5.2.1 Market Size, By Region, 2020-2026 (USD Billion)

5.3 Targeted Drugs & Immunotherapy

5.3.1 Market Size, By Region, 2020-2026 (USD Billion)

Chapter 6 Leukemia Market, By Mode of Administration

6.1 Mode of Administration Outlook

6.2 Oral Mode

6.2.1 Market Size, By Region, 2020-2026 (USD Billion)

6.3 Injectable Mode

6.3.1 Market Size, By Region, 2020-2026 (USD Billion)

Chapter 7 Leukemia Market, By Type

7.1 Type Outlook

7.2 Chronic Myeloid Leukemia

7.2.1 Market Size, By Region, 2020-2026 (USD Billion)

7.3 Chronic Lymphocytic Leukemia

7.3.1 Market Size, By Region, 2020-2026 (USD Billion)

7.4 Acute Lymphocytic Leukemia

7.4.1 Market Size, By Region, 2020-2026 (USD Billion)

7.5 Acute Myeloid Leukemia

7.5.1 Market Size, By Region, 2020-2026 (USD Billion)

Chapter 8 Leukemia Market, By Region

8.1 Regional outlook

8.2 North America

8.2.1 Market Size, By Country 2020-2026 (USD Billion)

8.2.2 Market Size, By Molecule Type, 2020-2026 (USD Billion)

8.2.3 Market Size, By Type, 2020-2026 (USD Billion)

8.2.4 Market Size, By Mode of Administration, 2020-2026 (USD Billion)

8.2.5 Market Size, By Treatment Type, 2020-2026 (USD Billion)

8.2.6 U.S.

8.2.6.1 Market Size, By Molecule Type, 2020-2026 (USD Billion)

8.2.6.2 Market Size, By Type, 2020-2026 (USD Billion)

8.2.6.3 Market Size, By Mode of Administration, 2020-2026 (USD Billion)

8.2.6.4 Market Size, By Treatment Type, 2020-2026 (USD Billion)

8.2.7 Canada

8.2.7.1 Market Size, By Molecule Type, 2020-2026 (USD Billion)

8.2.7.2 Market Size, By Type, 2020-2026 (USD Billion)

8.2.7.3 Market Size, By Mode of Administration, 2020-2026 (USD Billion)

8.2.7.4 Market Size, By Treatment Type, 2020-2026 (USD Billion)

8.3 Europe

8.3.1 Market Size, By Country 2020-2026 (USD Billion)

8.3.2 Market Size, By Molecule Type, 2020-2026 (USD Billion)

8.3.3 Market Size, By Type, 2020-2026 (USD Billion)

8.3.4 Market Size, By Mode of Administration, 2020-2026 (USD Billion)

8.3.5 Market Size, By Treatment Type, 2020-2026 (USD Billion)

8.3.6 Germany

8.3.6.1 Market Size, By Molecule Type, 2020-2026 (USD Billion)

8.3.6.2 Market Size, By Type, 2020-2026 (USD Billion)

8.3.6.3 Market Size, By Mode of Administration, 2020-2026 (USD Billion)

8.3.6.4 Market Size, By Treatment Type, 2020-2026 (USD Billion)

8.3.7 UK

8.3.7.1 Market Size, By Molecule Type, 2020-2026 (USD Billion)

8.3.7.2 Market Size, By Type, 2020-2026 (USD Billion)

8.3.7.3 Market Size, By Mode of Administration, 2020-2026 (USD Billion)

8.3.7.4 Market Size, By Treatment Type, 2020-2026 (USD Billion)

8.3.8 France

8.3.8.1 Market Size, By Molecule Type, 2020-2026 (USD Billion)

8.3.8.2 Market Size, By Type, 2020-2026 (USD Billion)

8.3.8.3 Market Size, By Mode of Administration, 2020-2026 (USD Billion)

8.3.8.4 Market Size, By Treatment Type, 2020-2026 (USD Billion)

8.3.9 Italy

8.3.9.1 Market Size, By Molecule Type, 2020-2026 (USD Billion)

8.3.9.2 Market Size, By Type, 2020-2026 (USD Billion)

8.3.9.3 Market Size, By Mode of Administration, 2020-2026 (USD Billion)

8.3.9.4 Market Size, By Treatment Type, 2020-2026 (USD Billion)

8.3.10 Spain

8.3.10.1 Market Size, By Molecule Type, 2020-2026 (USD Billion)

8.3.10.2 Market Size, By Type, 2020-2026 (USD Billion)

8.3.10.3 Market Size, By Mode of Administration, 2020-2026 (USD Billion)

8.3.10.4 Market Size, By Treatment Type, 2020-2026 (USD Billion)

8.3.11 Russia

8.3.11.1 Market Size, By Molecule Type, 2020-2026 (USD Billion)

8.3.11.2 Market Size, By Type, 2020-2026 (USD Billion)

8.3.11.3 Market Size, By Mode of Administration, 2020-2026 (USD Billion)

8.3.11.4 Market Size, By Treatment Type, 2020-2026 (USD Billion)

8.4 Asia Pacific

8.4.1 Market Size, By Country 2020-2026 (USD Billion)

8.4.2 Market Size, By Molecule Type, 2020-2026 (USD Billion)

8.4.3 Market Size, By Type, 2020-2026 (USD Billion)

8.4.4 Market Size, By Mode of Administration, 2020-2026 (USD Billion)

8.4.5 Market Size, By Treatment Type, 2020-2026 (USD Billion)

8.4.6 China

8.4.6.1 Market Size, By Molecule Type, 2020-2026 (USD Billion)

8.4.6.2 Market Size, By Type, 2020-2026 (USD Billion)

8.4.6.3 Market Size, By Mode of Administration, 2020-2026 (USD Billion)

8.4.6.4 Market Size, By Treatment Type, 2020-2026 (USD Billion)

8.4.7 India

8.4.7.1 Market Size, By Molecule Type, 2020-2026 (USD Billion)

8.4.7.2 Market Size, By Type, 2020-2026 (USD Billion)

8.4.7.3 Market Size, By Mode of Administration, 2020-2026 (USD Billion)

8.4.7.4 Market Size, By Treatment Type, 2020-2026 (USD Billion)

8.4.8 Japan

8.4.8.1 Market Size, By Molecule Type, 2020-2026 (USD Billion)

8.4.8.2 Market Size, By Type, 2020-2026 (USD Billion)

8.4.8.3 Market Size, By Mode of Administration, 2020-2026 (USD Billion)

8.4.8.4 Market Size, By Treatment Type, 2020-2026 (USD Billion)

8.4.9 Australia

8.4.9.1 Market Size, By Molecule Type, 2020-2026 (USD Billion)

8.4.9.2 Market size, By Type, 2020-2026 (USD Billion)

8.4.9.3 Market Size, By Mode of Administration, 2020-2026 (USD Billion)

8.4.9.4 Market Size, By Treatment Type, 2020-2026 (USD Billion)

8.4.10 South Korea

8.4.10.1 Market Size, By Molecule Type, 2020-2026 (USD Billion)

8.4.10.2 Market Size, By Type, 2020-2026 (USD Billion)

8.4.10.3 Market Size, By Mode of Administration, 2020-2026 (USD Billion)

8.4.10.4 Market Size, By Treatment Type, 2020-2026 (USD Billion)

8.5 Latin America

8.5.1 Market Size, By Country 2020-2026 (USD Billion)

8.5.2 Market Size, By Molecule Type, 2020-2026 (USD Billion)

8.5.3 Market Size, By Type, 2020-2026 (USD Billion)

8.5.4 Market Size, By Mode of Administration, 2020-2026 (USD Billion)

8.5.5 Market Size, By Treatment Type, 2020-2026 (USD Billion)

8.5.6 Brazil

8.5.6.1 Market Size, By Molecule Type, 2020-2026 (USD Billion)

8.5.6.2 Market Size, By Type, 2020-2026 (USD Billion)

8.5.6.3 Market Size, By Mode of Administration, 2020-2026 (USD Billion)

8.5.6.4 Market Size, By Treatment Type, 2020-2026 (USD Billion)

8.5.7 Mexico

8.5.7.1 Market Size, By Molecule Type, 2020-2026 (USD Billion)

8.5.7.2 Market Size, By Type, 2020-2026 (USD Billion)

8.5.7.3 Market Size, By Mode of Administration, 2020-2026 (USD Billion)

8.5.7.4 Market Size, By Treatment Type, 2020-2026 (USD Billion)

8.5.8 Argentina

8.5.8.1 Market Size, By Molecule Type, 2020-2026 (USD Billion)

8.5.8.2 Market Size, By Type, 2020-2026 (USD Billion)

8.5.8.3 Market Size, By Mode of Administration, 2020-2026 (USD Billion)

8.5.8.4 Market Size, By Treatment Type, 2020-2026 (USD Billion)

8.6 MEA

8.6.1 Market Size, By Country 2020-2026 (USD Billion)

8.6.2 Market Size, By Molecule Type, 2020-2026 (USD Billion)

8.6.3 Market Size, By Type, 2020-2026 (USD Billion)

8.6.4 Market Size, By Mode of Administration, 2020-2026 (USD Billion)

8.6.5 Market Size, By Treatment Type, 2020-2026 (USD Billion)

8.6.6 Saudi Arabia

8.6.6.1 Market Size, By Molecule Type, 2020-2026 (USD Billion)

8.6.6.2 Market Size, By Type, 2020-2026 (USD Billion)

8.6.6.3 Market Size, By Mode of Administration, 2020-2026 (USD Billion)

8.6.6.4 Market Size, By Treatment Type, 2020-2026 (USD Billion)

8.6.7 UAE

8.6.7.1 Market Size, By Molecule Type, 2020-2026 (USD Billion)

8.6.7.2 Market Size, By Type, 2020-2026 (USD Billion)

8.6.7.3 Market Size, By Mode of Administration, 2020-2026 (USD Billion)

8.6.7.4 Market Size, By Treatment Type, 2020-2026 (USD Billion)

8.6.8 South Africa

8.6.8.1 Market Size, By Molecule Type, 2020-2026 (USD Billion)

8.6.8.2 Market Size, By Type, 2020-2026 (USD Billion)

8.6.8.3 Market Size, By Mode of Administration, 2020-2026 (USD Billion)

8.6.8.4 Market Size, By Treatment Type, 2020-2026 (USD Billion)

Chapter 9 Company Landscape

9.1 Competitive Analysis, 2020

9.2 Novartis AG

9.2.1 Company Overview

9.2.2 Financial Analysis

9.2.3 Strategic Positioning

9.2.4 Info-Graphic Analysis

9.3 AbbVie

9.3.1 Company Overview

9.3.2 Financial Analysis

9.3.3 Strategic Positioning

9.3.4 Info-Graphic Analysis

9.4 Bristol-Myers Squibb

9.4.1 Company Overview

9.4.2 Financial Analysis

9.4.3 Strategic Positioning

9.4.4 Info-Graphic Analysis

9.5 F. Hoffmann-La Roche

9.5.1 Company Overview

9.5.2 Financial Analysis

9.5.3 Strategic Positioning

9.5.4 Info-Graphic Analysis

9.6 Sanofi

9.6.1 Company Overview

9.6.2 Financial Analysis

9.6.3 Strategic Positioning

9.6.4 Info-Graphic Analysis

9.7 Celgene Corporation

9.7.1 Company Overview

9.7.2 Financial Analysis

9.7.3 Strategic Positioning

9.7.4 Info-Graphic Analysis

9.8 Pfizer.

9.8.1 Company Overview

9.8.2 Financial Analysis

9.8.3 Strategic Positioning

9.8.4 Info-Graphic Analysis

9.9 Amgen

9.9.1 Company Overview

9.9.2 Financial Analysis

9.9.3 Strategic Positioning

9.9.4 Info-Graphic Analysis

9.10 Takeda

9.10.1 Company Overview

9.10.2 Financial Analysis

9.10.3 Strategic Positioning

9.10.4 Info-Graphic Analysis

9.11 Gilead Sciences

9.11.1 Company Overview

9.11.2 Financial Analysis

9.11.3 Strategic Positioning

9.11.4 Info-Graphic Analysis

9.12 Other Companies

9.12.1 Company Overview

9.12.2 Financial Analysis

9.12.3 Strategic Positioning

9.12.4 Info-Graphic Analysis

The Global Leukemia Market has been studied from the year 2019 till 2026. However, the CAGR provided in the report is from the year 2021 to 2026. The research methodology involved three stages: Desk research, Primary research, and Analysis & Output from the entire research process.

The desk research involved a robust background study which meant referring to paid and unpaid databases to understand the market dynamics; mapping contracts from press releases; identifying the key players in the market, studying their product portfolio, competition level, annual reports/SEC filings & investor presentations; and learning the demand and supply-side analysis for the Leukemia Market.

The primary research activity included telephonic conversations with more than 50 tier 1 industry consultants, distributors, and end-use product manufacturers.

Finally, based on the above thorough research process, an in-depth analysis was carried out considering the following aspects: market attractiveness, current & future market trends, market share analysis, SWOT analysis of the company and customer analytics.

We value your investment and offer free customization with every report to fulfil your exact research needs.

This website is secure and your personal details are safe. Privacy

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

What is the projected market size of the global leukemia market?

The global leukemia market size is projected to grow from USD 13.21 billion in 2021 to USD 19.52 billion by 2026, at a CAGR of 6.52% during the forecast period.

Who are the major vendors in the leukemia market?

Key and innovative vendors in the leukemia market include F. Hoffmann-La Roche AG, Bristol-Myers Squibb Company, AbbVie, Inc., Sanofi, Amgen, Gilead Sciences, Celgene Corporation, Pfizer, Inc., Novartis AG, and Takeda Pharmaceutical Company Limited.

Which region has the highest market share in the leukemia market?

North America is estimated to hold the highest market share in the leukemia market.

What is the Covid-19 impact on future leukemia manufacturers?

Globally, Covid-19 impact on the future leukemia market will be quite significant for the manufacturers. North America would be leading because of the increasing expenses in the healthcare sector and increasing investments in cell-based R&D activities. Subsequently, the Asia Pacific market will be growing the fastest because of the increasing awareness of leukemia and the growing medical tourism industry.

What are the major drivers in the leukemia market?

The major driving factors for the leukemia market include rising incidence of acute & chronic myeloid leukemia; rising research & developmental activities to launch non-invasive and advanced therapeutics for cancer treatment; increasing government expenditure on healthcare infrastructure; growing government initiatives for cancer awareness.